The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Opioid Receptor Gene (OPRM1, OPRK1, and OPRD1) Variants and Response to Naltrexone Treatment for Alcohol Dependence: Results From the VA Cooperative Study
Abstract
Background: Pharmacotherapy of alcohol dependence (AD) is at an early stage of development; currently available medications have limited efficacy. It would be clinically valuable to identify, before initiation of a course of treatment, those patients who, based on genetic markers, are most likely to respond to a specific pharmacotherapy. A previous report suggested that a functional variant at the genetic locus encoding the μ opioid receptor (Asn40Asp) is such a marker, in short‐term (3‐month) treatment with the opioid‐blocking drug naltrexone (NTX). Methods: We studied polymorphic variants at each of the 3 opioid receptor genes—OPRM1, OPRD1, and OPRK1, which encode the μ, δ, and κ opioid receptors, respectively—including the OPRM1 Asn40Asp variant—as predictors of response to NTX or placebo in 215 alcohol‐dependent male subjects who participated in Veterans Affairs Cooperative Study 425, “Naltrexone in the Treatment of Alcohol Dependence.” Results: At the 3‐month time point, treatment condition, age, and the pretreatment number of drinks per drinking day were all significant (p<0.05) predictors of the rate of relapse and time to relapse. Although NTX had no significant effect on relapse to heavy drinking in the overall sample in CSP 425, it significantly reduced relapse in the subgroup that provided DNA for analysis (i.e., the present study sample). There were no significant interactions between any individual single nucleotide polymorphisms studied and NTX treatment response. Conclusions: These results do not support association of the OPRM1 Asn40Asp polymorphism with NTX treatment response for AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The brief symptom inventory: an introductory report.
Derogatis, L. R., & Melisaratos, N. (1983) · Psychological Medicine · doi:10.1017/s0033291700048017 · Cited by 6,650
Naltrexone in the Treatment of Alcohol Dependence
Krystal, J. H., Cramer, J. A., Krol, W. F., Kirk, G. F., & Rosenheck, R. A. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011127 · Cited by 618
Self-citationOslin, D. W., Berrettini, W., Kranzler, H. R., Pettinati, H., Gelernter, J., Volpicelli, J. R., & O'Brien, C. P. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300219 · Cited by 571
Self-citationAllelic Expression Imbalance of Human mu Opioid Receptor (OPRM1) Caused by Variant A118G
Zhang, Y., Wang, D., Johnson, A. D., Papp, A. C., & Sadée, W. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m504942200 · Cited by 563
Pharmacological Treatment of Alcohol Dependence: A Review of the Evidence
Garbutt, J. C., West, S. L., Carey, T. S., Lohr, K. N., & Crews, F. T. (1999) · JAMA · doi:10.1001/jama.281.14.1318 · Cited by 444 · cited 1×
“Food and Drug Administration (FDA) for treatment of the disorder—disulfiram, naltrexone (NTX; both an oral formulation and a long-acting one), and acamprosate— these drugs produce substantial benefit in only a minority of patients (Bouza et al., 2005; Fuller et al., 1986; Garbutt et al., 1999; Kranzler and Van Kirk, 2…”
BackgroundDisulfiram Treatment of Alcoholism: A Veterans Administration Cooperative Study
Fuller, R. K. (1986) · JAMA · doi:10.1001/jama.1986.03380110055026 · Cited by 431
Allelic and haplotypic association of GABRA2 with alcohol dependence
Covault, J., Gelernter, J., Hesselbrock, V., Nellissery, M., & Kranzler, H. R. (2004) · American Journal of Medical Genetics Part B Neuropsychiatric Genetics · doi:10.1002/ajmg.b.30091 · Cited by 273 · cited 1×
“There is a growing understanding of genes that increase risk for AD—the past few years have witnessed the identification and replication of several risk genes acting via GABAergic (Edenberg et al., 2004; Covault et al., 2004; Lappalainen et al., 2005), muscarinic (Luo et al.”
BackgroundStreeton, C. (2001) · Alcohol and Alcoholism · doi:10.1093/alcalc/36.6.544 · Cited by 228
Cited by
Opioid antagonists for alcohol dependence
Srisurapanont, M., & Jarusuraisin, N. (2002) · The Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001867 · Cited by 764
Schuckit, M. A. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60009-x · Cited by 712
Alcoholism: A Systems Approach From Molecular Physiology to Addictive Behavior
Spanagel, R. (2009) · Physiological Reviews · doi:10.1152/physrev.00013.2008 · Cited by 634
Anton, R. F., Oroszi, G., O’Malley, S., Couper, D., Swift, R., Pettinati, H., & Goldman, D. (2008) · Archives of General Psychiatry · doi:10.1001/archpsyc.65.2.135 · Cited by 451
Relatively strong automatic appetitive action‐tendencies in male carriers of the OPRM1 G‐allele
Wiers, R. W., Rinck, M., Dictus, M., & Van Den Wildenberg, E. (2009) · Genes, Brain and Behavior · doi:10.1111/j.1601-183x.2008.00454.x · Cited by 377
Metadata
- Authors
- Gelernter, J., Gueorguieva, R., Kranzler, H. R., Zhang, H., Cramer, J., Rosenheck, R., Krystal, J. H., & the VA Cooperative Study #425 Study Group
- Venue
- Alcoholism: Clinical and Experimental Research
- Publisher
- Wiley
- Published
- 2007-02-12
- Volume
- 31
- Issue
- 4
- Pages
- 555-563
- ISSN
- 0145-6008 (ISSN-L)
- 1530-0277
- OpenAlex
- W2024605730
- Cited by
- 200
- References
- 8
- FWCI
- 12.56
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Opioid Receptor Gene (OPRM1, OPRK1, and OPRD1) Variants and Response to Naltrexone Treatment for Alcohol Dependence: Results From the VA Cooperative Study. https://app.cochat.ai/papers/10.1111/j.1530-0277.2007.00339.x
- The paper
- Gelernter, J., Gueorguieva, R., Kranzler, H. R., Zhang, H., Cramer, J., Rosenheck, R., Krystal, J. H., & the VA Cooperative Study #425 Study Group. (2007). Opioid Receptor Gene (OPRM1, OPRK1, and OPRD1) Variants and Response to Naltrexone Treatment for Alcohol Dependence: Results From the VA Cooperative Study. Alcoholism: Clinical and Experimental Research. https://doi.org/10.1111/j.1530-0277.2007.00339.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.